GALT, US3632252025

Galectin Therapeutics stock has November 13 earnings, USD -0.05 estimate

Published on 10/17/2026 at 19:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

June 30 earnings per share were USD -0.14. Galectin Therapeutics stock was USD 3.62 on October 16, 2026, down 2.43 percent on Nasdaq.

Upcoming results and valuation

MarketBeat estimates third-quarter 2026 earnings for November 13, 2026, at USD -0.05 per share.
For the quarter ended June 30, 2026, Galectin Therapeutics reported USD -0.14 earnings per share against a USD -0.09 consensus estimate.
Galectin Therapeutics stock was USD 3.62 at 4:00 p.m. ET on October 16, 2026, down 2.43 percent versus the Nasdaq prior close of USD 3.71.
Market capitalization stood at USD 238.4 million and the P/E ratio was -8.48 on October 16, 2026.

GALT, US3632252025, Illustration mit AI erstellt.

Galectin Therapeutics Inc. (US3632252025) is estimated to report third-quarter 2026 earnings on November 13, 2026, with consensus earnings per share of USD -0.05, according to MarketBeat. The last Nasdaq price was USD 3.62 on October 16, 2026 at 4:00 p.m. ET, down 2.43 percent from the USD 3.71 prior close.

June results set the earnings baseline

The latest reported quarter ended June 30, 2026. Galectin Therapeutics reported earnings per share of USD -0.14, missing the USD -0.09 consensus estimate by USD 0.05, according to MarketBeat. The result gives the November report a clear comparison point.

Nasdaq price stays below the yearly high

Galectin Therapeutics was last at USD 3.62 on Nasdaq on October 16, 2026 at 4:00 p.m. ET. Its 52-week range was USD 2.03 to USD 7.13, leaving the price 78.33 percent above the low and 49.23 percent below the high. Trading volume was 169,419 shares against an average of 314,685 shares on the same date.

Valuation and the November date

The company had a market capitalization of USD 238.4 million and a P/E ratio of -8.48 as of October 16, 2026. The November 13, 2026 report is listed for the third quarter, with an earnings call scheduled for 9:30 a.m. ET, according to MarketBeat.

Galectin Therapeutics is a biotechnology company developing therapies that target galectin-3. Its lead investigational product is belapectin, which is being studied in liver disease and cancer programs.

Nasdaq price remains the market marker

The last Nasdaq quote stood at USD 3.62 on October 16, 2026 at 4:00 p.m. ET, down 2.43 percent versus the Nasdaq prior close of USD 3.71. The next scheduled company date is November 13, 2026.